EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors

Modern Pathology

Volumn 22, Issue 10, 2009, Pages 1328-1340

  Dobashi, Yoh ^a   Suzuki, Shioto ^b   Sato, Eiichi ^c   Hamada, Yoshiki ^b   Yanagawa, Takashi ^d   Ooi, Akishi ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; Bone and soft tissue tumors; EGFR; Molecular targeting therapy; MTOR; Phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; S6 KINASE;

ARTICLE; BONE TISSUE; BONE TUMOR; ENZYME ACTIVATION; GENE ACTIVATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; NERVE SHEATH; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOFT TISSUE TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BONE NEOPLASMS; CELL PROLIFERATION; ENZYME ACTIVATION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM STAGING; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 70349696530     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.104     Document Type: Article

References (46)

1. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007-1018.
2. Mita MM, Tolcher AW. The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep 2007;9: 316-322.
3. de Alava E. Molecular pathology in sarcomas. Clin Transl Oncol 2007;9:130-144.
4. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005;23:6172-6180.
5. Dobashi Y, Takei N, Suzuki S, et al. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol 2004;17:1497-1505.
6. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 2005;103:1881-1890.
7. Dobashi Y, Suzuki S, Sugawara H, et al. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol 2007;38:914-925.
8. Mamane Y, Petroulakis E, LeBacquer O, et al. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-6422.
9. Riemenschneider MJ, Betensky RA, Pasedag SM, et al. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 2006;66:5618-5623.
10. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
11. Lee CH, Inoki K, Karbowniczek M, et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J 2007;26:4812-4823.
12. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
13. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
14. Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006;94:195-199.
15. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-216.
16. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004;16:564-575.
17. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-4973.
18. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66:10040-10047.
19. Petricoin 3rd EF, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-3440.
20. Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1 alpha/VEGF signaling. Neoplasia 2006;8:394-401.
21. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetic of Tumours of Soft Tissue and Bone. IARC Press: Lyon, 2002.
22. Suzuki S, Igarashi S, Hanawa M, et al. Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol 2006;19:986-998.
23. Dobashi Y, Suzuki S, Matsubara H, et al. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 2009;115:107-118.
24. Wu F, Liu SY, Tao YM, et al. Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma. Cancer 2008;112:2002-2010.
25. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-822.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174.
27. Armengol G, Rojo F, Castellvi J, et al. 4E-binding protein 1: a key molecular 'funnel factor' in human cancer with clinical implications. Cancer Res 2007;67:7551-7555.
28. Cen L, Arnoczky KJ, Hsieh FC, et al. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 2007;20:936-946.
29. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003;163:1449-1456.
30. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/ gefitinib in the therapy of a sacral chordoma. Onkologie 2006;29:572-574.
31. Ohanna M, Sobering AK, Lapointe T, et al. Atrophy of S6K1(+/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol 2005;7:286-294.
32. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006;18:360-362.
33. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059.
34. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005;280: 25485-25490.
35. Castellvi J, Garcia A, Rojo F, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006;107:1801-1811.
36. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin- associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA 2000;97: 14340-14345.
37. Rong L, Livingstone M, Sukarieh R, et al. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 2008;14:1318-1327.
38. Wang ML, Panasyuk G, Gwalter J, et al. Regulation of ribosomal protein S6 kinases by ubiquitination. Biochem Biophys Res Commun 2008;369:382-387.
39. Liu L, Chen L, Chung J, et al. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008;27:4998-5010.
40. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-1487.
41. Phornphutkul C, Wu KY, Auyeung V, et al. mTOR signaling contributes to chondrocyte differentiation. Dev Dyn 2008;237:702-712.
42. Yeh WC, Bierer BE, McKnight SL. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3- L1 cells. Proc Natl Acad Sci USA 1995;92:11086-11090.
43. Kim JE, Chen J. regulation of peroxisome proliferatoractivated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004;53:2748-2756.
44. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004;10:6779-6788.
45. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65: 2406-2411.
46. Merimsky O, Gorzalczany Y, Sagi-Eisenberg R. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol 2007;31:225-232.